Drug and asset intelligence for Romvimza (Vimselitinib) with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Deciphera Pharmaceuticals →

Recent signals(2)

RegulatoryJuly 3, 2026

FDA Accepts Supplement for Romvimza (Vimselitinib) by Deciphera Pharmaceuticals

The FDA has accepted a supplemental NDA for Romvimza (Vimselitinib) from Deciphera Pharmaceuticals.

RegulatoryJuly 1, 2026

FDA Accepts Supplemental NDA for Romvimza (Vimselitinib) by Deciphera Pharmaceuticals

The FDA has accepted a supplemental NDA for Romvimza (vimselitinib) submitted by Deciphera Pharmaceuticals.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

Deciphera Pharmaceuticals — Romvimza (Vimselitinib)

Monitor for further updates on the review timeline and any potential approval outcomes.

July 3, 2026 · N/A

Topline Data

Deciphera Pharmaceuticals — Romvimza (vimselitinib)

Monitor the timeline for the FDA review process and any upcoming data releases related to vimselitinib's efficacy and safety.

July 1, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Oncology →

Oncology · Small Molecule →

Small Molecule →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.